A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma.
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2012
At a glance
- Drugs Temozolomide (Primary) ; Benzylguanine
- Indications Glioma
- Focus Therapeutic Use
- 25 Jan 2012 Planned End Date changed from 1 Dec 2008 to 1 Feb 2009 as reported by ClinicalTrials.gov.
- 13 Feb 2009 Status changed from active, no longer recruiting to discontinued, as reported by clinicaltrials.gov. AOI Pharmaceuticals decided to terminate the license agreement.
- 04 Apr 2008 The expected estimated study completion date for this trial has changed from December 2007 to December 2008 according to ClinicalTrials.gov. The estimated final data collection date for the primary outcome measure is June 2008.